Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 24 Nov, 25 | NBIX | Buy | USD 141.83 | USD 149.0 | USD 158.0 | 2 days | Closed |
8.24%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Strong Net Income Growth: Net income rose from USD 129.8 million in Q3 FY24 to USD 209.5 million in Q3 FY25, an improvement of USD 79.7 million, reflecting enhanced profitability and strong operating leverage despite increased expenses
Significant Revenue Expansion: Total revenues increased from USD 622.1 million in Q3 FY24 to USD 794.9 million in Q3 FY25, representing a growth of USD 172.8 million. This increase was driven by higher INGREZZA sales and incremental contributions from CRENESSITY following its launch
Increased Selling, General, and Administrative Expenses: SG&A expenses rose from USD 234.3 million in Q3 FY24 to USD 291.6 million in Q3 FY25, an increase of USD 57.3 million, due to expanded commercial support and promotional spending for multiple products
Higher Research and Development Costs: R&D expenses increased from USD 195.0 million in Q3 FY24 to USD 250.0 million in Q3 FY25, representing an increase of USD 55.0 million. This reflects intensified development activities and milestone-related outlays
Neurocrine Biosciences faces significant investment risk arising from high dependence on its flagship products, escalating R&D and SG&A spending, competitive threats including generic challenges, and uncertainties inherent in clinical development and regulatory approvals, any of which could materially affect future financial performance
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 141.83 | 125.0 | 149.0 | 158.0 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Revenue Performance: Neurocrine Biosciences reported a substantial year-over-year increase in revenues for the quarter ended September 30, 2025. Total revenues rose to USD 794.9 million, compared with USD 622.1 million in the prior-year quarter, driven primarily by the growth of INGREZZA and the addition of CRENESSITY to the commercial portfolio . INGREZZA generated USD 686.6 million in net product sales, while CRENESSITY contributed USD 98.1 million, reflecting successful commercialization efforts and expansion across multiple therapeutic categories.
Operating Expense Trends: Operating expenses increased significantly relative to the prior year, reaching USD 555.9 million in Q3 FY25 compared to USD 438.3 million in Q3 FY24. The growth was largely attributable to higher research and development (R&D) spending and increased selling, general, and administrative (SG&A) expenses, associated with expanded clinical programs and commercial activities supporting product launches and lifecycle management initiatives.
Research and Development Investments: R&D expenditures rose to USD 250.0 million from USD 195.0 million in the prior-year period, reflecting ongoing advancement of the company’s diversified pipeline. Increased costs related to external research, personnel, and milestone payments contributed to the rise. These investments underscore the company’s continued focus on expanding therapeutic options across neuroscience indications.
Commercial and Administrative Costs: Selling, general, and administrative expenses totaled USD 291.6 million for Q3 FY25, compared with USD 234.3 million in Q3 FY24. The increase was driven by promotional activities, market expansion efforts, and support for both the INGREZZA and CRENESSITY franchises. The higher spend reflects Neurocrine’s strategic emphasis on strengthening commercial operations and sustaining market growth for key products.
Profitability and Earnings Growth: Despite higher operating costs, the company delivered strong profitability. Operating income improved to USD 239.0 million from USD 183.8 million, supported by revenue growth and effective cost management. Net income increased to USD 209.5 million, compared with USD 129.8 million a year earlier, reinforcing the company’s enhanced earnings trajectory and successful execution across its commercial and R&D platforms.
Other Income and Financial Activities: Other income rose substantially to USD 52.8 million, compared to USD 6.5 million in the prior-year quarter. This improvement was primarily due to unrealized gains on equity investments, which shifted from a loss position in the prior period. Strong investment income supported overall earnings, further strengthening the company’s financial position.
Overall Financial Position: The quarter demonstrated solid operational and financial progress, characterized by diversified revenue contributions, expanding R&D activities, and strong earnings growth. Neurocrine’s strategic investments in both its commercial portfolio and clinical pipeline continue to reinforce its long-term growth outlook and competitive positioning in neuroscience therapeutics.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given on Neurocrine Biosciences, Inc (NASDAQ: NBIX) at the closing market price of USD 141.83, as on Nov 21, 2025.
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences Inc |
1.42 1.03% | 139.05 | 41.02 | 23.47 | 4.96 | 4.72 | 4.76 | 20.52 |
| ZTS Zoetis Inc |
-2.49 1.99% | 122.45 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.91 3.05% | 28.96 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 150.82 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.065 0.37% | 17.43 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on November 24, 2025. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned has been achieved and is subject to the factors discussed above.
Note 4: StockNextt reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2026 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
